Skip to content

A randomized controlled trial for Shugan Tiaoshen integrated program of acupuncture and moxibustion in the treatment of moderate depressive disorder

A randomized controlled trial for Shugan Tiaoshen integrated program of acupuncture and moxibustion in the treatment of moderate depressive disorder

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100042841
Enrollment
Unknown
Registered
2021-01-30
Start date
2021-03-01
Completion date
Unknown
Last updated
2021-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive disorder

Interventions

Sponsors

Guangdong Hospital of traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. The results were in accordance with the diagnostic criteria of traditional Chinese and Western medicine; 2. Age 18-65 years old, junior high school or above; 3. The 17 item Hamilton Depression Scale (HAMD-17) scores were more than 17 and less than 24; 4. They signed informed consent and volunteered to participate in this study. Only those who meet the above 4 items can be included in the study.

Exclusion criteria

Exclusion criteria: 1. Those with suicidal tendency; 2. Previous diagnosis of mental retardation, schizophrenia, bipolar disorder, substance abuse (such as alcohol dependence) or other mental disorders; 3. History of epilepsy, family history of strong positive epilepsy, history of brain organic diseases and severe somatic diseases; 4. Those who are taking antidepressants within 6 weeks (including 6 weeks); 5. Pregnancy, pregnancy preparation or lactation; 6. Patients with skin lesions or skin diseases, severe diabetes mellitus, tumor and important organ dysfunction, or severe internal diseases such as liver, kidney, cardiovascular, endocrine, respiratory and hematopoietic systems; Those who met any of the above criteria were excluded from the study.

Design outcomes

Primary

MeasureTime frame
HAMD-17;

Secondary

MeasureTime frame
PHQ-9;PSQI;HAMA;Actigraphy;

Countries

China

Contacts

Public ContactFu Wenbin

The Second Clinical Medical College, Guangzhou University of traditional Chinese Medicine

fuwenbin@139.com+86 13808888626

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026